Tricuspid Valve

This channel is dedicated to news and trends in tricuspid valve interventions, surgical and transcatheter, to manage regurgitation and valve stenosis. The tricuspid valve is a rapidly growing area in structural heart interventions. Minimally invasive transcatheter tricuspid valve replacement (TTVR) and repair using transcatheter edge to edge repair (TEER) clips are expected to become a new standard of care in the next couple years, partly because open heart tricuspid surgery has historically has poor outcomes.

Cardiologist shares positive first-in-human data on TriCares TTVR device
The new Topaz TTVR system was associated with the consistent elimination of tricuspid regurgitation. In addition, none of the first 20 patients treated with the device required a permanent pacemaker as a result of the procedure.
No longer the ‘forgotten valve’: Tricuspid valve surgery outcomes keep improving
Patient outcomes after tricuspid valve replacement have improved significantly over the years, according to new data published in The Annals of Thoracic Surgery.
CMS proposes Medicare coverage for T-TEER
CMS has proposed covering tricuspid TEER for patients who present with symptomatic tricuspid regurgitation despite optimal medical therapy. The agency still has questions about the available data, however, and is seeking public comments as it makes its final decision.
First comprehensive T-TEER resource examines best practices for tricuspid valve repair
"We wanted to ensure that every interventionalist, regardless of location or resources, has access to the best information possible," one co-author said.
Key trends in transcatheter tricuspid valve interventions
Steven Bolling, MD, noted that tricuspid treatments have been linked to consistent benefits in terms of quality of life. However, he said, finding clear improvements in clinical outcomes has been more challenging.

Topaz transcatheter tricuspid valve replacement (TTVR) system TriCares

Cardiologist shares positive first-in-human data on TriCares TTVR device

The new Topaz TTVR system was associated with the consistent elimination of tricuspid regurgitation. In addition, none of the first 20 patients treated with the device required a permanent pacemaker as a result of the procedure.

No longer the ‘forgotten valve’: Tricuspid valve surgery outcomes keep improving

Patient outcomes after tricuspid valve replacement have improved significantly over the years, according to new data published in The Annals of Thoracic Surgery.

Abbott has received approval from the U.S. Food and Drug Administration (FDA) for its TriClip transcatheter edge-to-edge repair (TEER) system designed to treat tricuspid regurgitation (TR).

CMS proposes Medicare coverage for T-TEER

CMS has proposed covering tricuspid TEER for patients who present with symptomatic tricuspid regurgitation despite optimal medical therapy. The agency still has questions about the available data, however, and is seeking public comments as it makes its final decision.

An FDA panel will discuss its recommendations related to Abbott's TriClip G4 transcatheter edge-to-edge repair (TEER) system for tricuspid regurgitation.

First comprehensive T-TEER resource examines best practices for tricuspid valve repair

"We wanted to ensure that every interventionalist, regardless of location or resources, has access to the best information possible," one co-author said.

Video of Steven Bolling, MD, professor of cardiac surgery, University of Michigan, explaining trends in tricuspid valve repair and replacement at CRT 2025.

Key trends in transcatheter tricuspid valve interventions

Steven Bolling, MD, noted that tricuspid treatments have been linked to consistent benefits in terms of quality of life. However, he said, finding clear improvements in clinical outcomes has been more challenging.

Edwards Lifesciences Corporation has shared new one-year data on the safety and effectiveness of its Evoque transcatheter tricuspid valve replacement (TTVR) system among patients with tricuspid regurgitation (TR)

CMS approves Medicare coverage for transcatheter tricuspid valve replacement

CMS will cover TTVR for the treatment of symptomatic tricuspid regurgitation on a national level. The agency first proposed such a policy in December, taking time to consider public comments before finalizing its decision.

Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

D. Scott Lim, MD, medical director of the Advanced Cardiac Valve Center, and co-director of the Adult Congenital Heart Disease Center at University of Virginia (UVA) Health in Charlottesville, and an associate professor at the University British Columbia, explains how intracardiac echo (ICE) is increasingly being used to help guide structural heart procedures.

Key details on the use of ICE to guide structural heart procedures

Scott Lim, MD, details his experience using intracardiac echo to help guide structural heart procedures with or without traditional TEE. One key benefit of ICE, he explained, is its ability to overcome imaging challenges posed by prior cardiac surgeries.